N-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
Grundinformationen
- CAS
174636-32-9- Standard-SMILES
CCC(NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1- InChIKey
BIAVGWDGIJKWRM-UHFFFAOYSA-N- Summenformel
- C25H22N2O2
- Durchschnittliche Molmasse
- 382,5 g/mol
- Monoisotopische Masse
- 382,16812795
Überblick
Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential antipsychotic drug for the treatment of schizophrenia.
Namen und Bezeichner
- Bevorzugter Name
- N-(alpha-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
- IUPAC
- 3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
- Englischer Name
- SB 223412
- Summenformel
- C25H22N2O2
- Molmasse
- 382.45
Namen und Synonyme
N-(alpha-Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamideRefChem:9269323-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide174636-26-1SCHEMBL74221CHEMBL2755443-Hydroxy-2-phenyl-quinoline-4-carboxylic acid (1-phenyl-propyl)-amideSCHEMBL29604291BDBM50074819PDSP1_001725PDSP2_001708AKOS027322596
Weitere Namen anzeigen
CS-1123SB 223412Talnetant (SB 223412)Talnetant, 10 mM in DMSOSB-223412SB223412SB 223412(S)-N-(1-Phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide(S)-3-Hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide3-Hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-4-quinolinecarboxamide
DB06429NS00120402L001526Q135661633-Hydroxy-2-phenyl-quinoline-4-carboxylic acid (1-phenyl-propyl)-amide (skb_a)
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 5,7
- Polarare Oberfläche (TPSA)
- 62,2 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 3
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 29
- Formalladung
- 0
- Komplexität
- 527
Physikochemische Eigenschaften
- Schmelzpunkt
- 125.1 · 125.1-126.2℃
- Siedepunkt
- 580.4 · 580.4±50.0 °C(Predicted)
- Dichte
- 1.212 · 1.212±0.06 g/cm3(Predicted)
- storage temp.
- 2 · Sealed in dry,2-8°C
- Löslichkeit
- 25 mg/mL, · DMSO: soluble25mg/mL, clear
- pka
- 6.7 · 6.70±0.50(Predicted)
- Aggregatzustand
- powder
- Farbe
- white to beige
- InChI
- 1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)/t20-/m0/s1
- InChIKey
- BIAVGWDGIJKWRM-FQEVSTJZSA-N
- SMILES
- OC(C(C(N[C@H](C1=CC=CC=C1)CC)=O)=C(C=CC=C2)C2=N3)=C3C4=CC=CC=C4
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- wgk
- WGK 3
- ridadr
- UN 2811 6.1 / PGIII
- risk_code
- 25
- hazard_code
- T
- safety_code
- 45
- Speicherklasse
- 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
- Hazard Classifications
- Acute Tox. 3 Oral
Chemie und Industrie
Anwendungen
BeschreibungTalnetant is an antagonist of the neurokinin-3 (NK3) receptor (Ki = 1 nM). It is selective for NK3 over NK1 and NK2 receptors (Kis = 144 and >100,000 nM, respectively, in CHO cells expressing recombinant human receptors). Talnetant inhibits calcium mobilization induced by neurokinin B in HEK293 cells expressing human NK3 receptors (IC50 = 16.6 nM). It inhibits contractions induced by the NK3 receptor agonist senktide in isolated rabbit iris sphincter muscle (pD2 = 9.1). Talnetant (5-20 mg/kg) reduces senktide-induced head shakes and tail whips in mice. It also inhibits senktide-induced wet-dog shakes, increases extracellular dopamine and norepinephrine in the medial prefrontal cortex, and attenuates haloperidol-induced increases in nucleus accumbens dopamine levels in guinea pigs.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
5
Notizen zur Verbindung
Wird geladen…